The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Expanding Family of SMARCB1(INI1)-deficient Neoplasia: Implications of Phenotypic, Biological, and Molecular Heterogeneity
Abstract
Since the description of atypical teratoid/rhabdoid tumors of the central nervous system and renal/extrarenal malignant rhabdoid tumors in children, the clinicopathologic spectrum of neoplasms having in common a highly variable rhabdoid cell component (0% to 100%) and consistent loss of nuclear SMARCB1 (INI1) expression has been steadily expanding to include cribriform neuroepithelial tumor of the ventricle, renal medullary carcinoma and a subset of collecting duct carcinoma, epithelioid sarcoma, subsets of miscellaneous benign and malignant soft tissue tumors, and rare rhabdoid carcinoma variants of gastroenteropancreatic, sinonasal, and genitourinary tract origin. Although a majority of SMARCB1-deficient neoplasms arise de novo, the origin of SMARCB1-deficient neoplasia in the background of a phenotypically or genetically definable differentiated SMARCB1-intact "parent neoplasm" has been convincingly demonstrated, highlighting the rare occurrence of rhabdoid tumors as "double-hit neoplasia." As a group, SMARCB1-deficient neoplasms occur over a wide age range (0 to 80 y), may be devoid of rhabdoid cells or display uniform rhabdoid morphology, and follow a clinical course that varies from benign to highly aggressive causing death within a few months irrespective of aggressive multimodality therapy. Generally applicable criteria that would permit easy recognition of these uncommon neoplasms do not exist. Diagnosis is based on site-specific and entity-specific sets of clinicopathologic, immunophenotypic, and/or molecular criteria. SMARCB1 immunohistochemistry has emerged as a valuable tool in confirming or screening for SMARCB1-deficient neoplasms. This review summarizes the different phenotypic and topographic subgroups of SMARCB1-deficient neoplasms including sporadic and familial, benign and malignant, and rhabdoid and nonrhabdoid variants, highlighting their phenotypic heterogeneity and molecular complexity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcription Activator Interactions with Multiple SWI/SNF Subunits
Neely, K. E., Hassan, A. H., Brown, C. E., Howe, L., & Workman, J. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1615-1625.2002 · Cited by 183
Cited by
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
Yatabe, Y., Dacic, S., Borczuk, A. C., Warth, A., Russell, P. A., Lantuejoul, S., Beasley, M. B., Thunnissen, E., Pelosi, G., Rekhtman, N., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.005 · Cited by 365
Rekhtman, N., Montecalvo, J., Chang, J. C., Alex, D., Ptashkin, R. N., Ai, N., Sauter, J. L., Kezlarian, B., Jungbluth, A., Desmeules, P., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.023 · Cited by 326
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131
Self-citation
Metadata
- Authors
- Agaimy, A.
- Venue
- Advances in Anatomic Pathology
- Published
- 2014-11
- Volume
- 21
- Issue
- 6
- Pages
- 394-410
- ISSN
- 1072-4109 (ISSN-L)
- OpenAlex
- W2052747035
- Cited by
- 163
- References
- 1
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Expanding Family of SMARCB1(INI1)-deficient Neoplasia: Implications of Phenotypic, Biological, and Molecular Heterogeneity. https://app.cochat.ai/papers/10.1097/pap.0000000000000038
- The paper
- Agaimy, A. (2014). The Expanding Family of SMARCB1(INI1)-deficient Neoplasia: Implications of Phenotypic, Biological, and Molecular Heterogeneity. Advances in Anatomic Pathology. https://doi.org/10.1097/pap.0000000000000038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.